3DProSeed StromaLine
Oncology (Tumor-Stroma Interaction Studies)
Key Facts
About Ectica Technologies
Ectica Technologies is a privately held spin-off from ETH Zurich and the University of Zurich, founded to commercialize innovative hydrogel technologies for pre-clinical drug discovery. The company's patented 3DProSeed® platform creates synthetic, animal-free models of the tumor stroma, addressing the critical need to incorporate tumor-stroma interactions into high-content screening assays. By providing physiologically relevant yet automation-compatible models, Ectica targets the growing demand for more predictive in vitro systems in oncology and fibrosis research. Its business model combines product sales (StromaLine models) with contract development and manufacturing services for tailored hydrogel formulations.
View full company profile